All In Biotech

NDA 219131 · Almatica

Duloxetine Hydrochloride

Duloxetine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Feb 27, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

410

121 Phase 3, 33 recruiting

FAERS reports

71,529

50,892 serious, 7,249 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. ( 5.1 )

What it is approved for

From the label in effect Mar 2, 2026.

Duloxetine Delayed-Release Capsules are indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Duloxetine Delayed-Release Capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 )

Mechanism: Although the exact mechanisms of the antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 27, 2026 Original approval · Type 5 - New Formulation or New Manufacturer Letter
3 products under this application
  • DULOXETINE HYDROCHLORIDE · DULOXETINE HYDROCHLORIDE EQ 90MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
  • DULOXETINE HYDROCHLORIDE · DULOXETINE HYDROCHLORIDE EQ 120MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
  • DULOXETINE HYDROCHLORIDE · DULOXETINE HYDROCHLORIDE EQ 80MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Duloxetine" as an intervention, any sponsor and status, largest first.

All 410 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,650
  • nausea5,341
  • fatigue5,240
  • off label use4,568
  • headache4,047
  • pain4,036
  • diarrhoea3,612
  • dizziness3,325
  • fall3,055
  • vomiting2,709
  • arthralgia2,568
  • dyspnoea2,547

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200416
200568
200672
2007163
2008381
2009328
2010447
2011358
2012434
2013594
20141,256
20152,297
20163,021
20173,872
20185,224
20196,102
20206,546
20216,173
20226,778
20236,673
20246,909
20257,671
20266,146

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 802 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.